Overview of Erythromycinum TZF
| Property | Description |
|---|---|
| Active Ingredient | Erythromycin |
| Form | Tablets, Capsules, Suspensions, Injections |
| Pharmacological Class | Macrolide Antibiotic |
| General Purpose | Counteracting bacterial infections |
| Origin | Natural Product (from Saccharopolyspora erythraea) |
Erythromycinum TZF: What is this Macrolide Antibiotic?
Erythromycinum TZF is a prescription-only medicinal product containing the active ingredient Erythromycin, formally recognized as an antibacterial agent. It belongs specifically to the macrolide antibiotic class, which is characterized by its unique large macrocyclic lactone ring structure. This drug operates through a specific mechanism against susceptible pathogens. This classification means it is chemically distinct from other antibiotic types and is a critical option for treating specific bacterial infections caused by susceptible organisms. This role makes it a fundamental tool in the treatment of various bacterial ailments, often utilized where penicillin allergies preclude the use of first-line agents.
Composition, Origin, and Available Forms
The core active substance, Erythromycin, is considered a natural product because its chemical entity is biosynthesized by the soil-dwelling bacterium Saccharopolyspora erythraea. Erythromycinum TZF is generally a single-ingredient product, though the formulation often uses a stabilized salt, such as Erythromycin Stearate or Ethylsuccinate, to ensure adequate stability within the gastrointestinal tract. It is available in diverse pharmaceutical preparations, including solid oral forms such as tablets and specialized capsules (like delayed-release pellets to protect the drug from stomach acid), liquid oral suspensions, and sterile preparations for intravenous (IV) injection. The choice of form allows for tailored administration based on patient requirements and provides versatility across systemic and localized infections.
General Therapeutic Purpose of Erythromycin
The overarching purpose of Erythromycinum TZF is to manage and control infections caused by susceptible bacteria. The drug achieves this general benefit through a bacteriostatic action; its function is to halt the growth and multiplication of the targeted bacteria. This mechanism, which involves interrupting the process of protein synthesis within the bacterial cell, prevents the bacteria from expanding their population and allows the body's natural defenses to resolve the infection. This method is frequently employed in scenarios requiring treatment against organisms that exhibit resistance to non-macrolide agents.
Regulatory References
